A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.
about
Pathogenesis of thrombotic microangiopathiesChallenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewalProteolytic processing of von Willebrand factor by adamts13 and leukocyte proteasesSingle domain antibodies: promising experimental and therapeutic tools in infection and immunityIncreased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivoPlatelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF.The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.The interaction between factor H and Von Willebrand factor.Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission.Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13Indications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura.Higher and lower active circulating VWF levels: different facets of von Willebrand disease.Type 2B von Willebrand disease with or without large multimers: A distinction of the two sides of the disorder is long overdueCleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity.Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.Platelet adhesion under flow.Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region.Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand diseasevon Willebrand factor, endothelial dysfunction, and cardiovascular disease.Increased active von Willebrand factor during disease development in the aging diabetic patient population.Endothelial activation, haemostasis and thrombosis biomarkers in Ugandan children with severe malaria participating in a clinical trial.No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variationNanotechnology in global medicine and human biosecurity: private interests, policy dilemmas, and the calibration of public health law.Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.Nanobody; an old concept and new vehicle for immunotargeting.von Willebrand factor: at the crossroads of bleeding and thrombosis.Novel therapy based on camelid nanobodies.Nanobodies as novel agents for disease diagnosis and therapy.Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha.Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.von Willebrand factor and inflammation.Platelet dysfunction contributes to bleeding complications in patients with probable leptospirosis.At least type VWD2B is a discrete variant of VWD, isn't it?Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study.Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia.The contribution of von Willebrand factor-GPIbα interactions to persistent aggregate formation in apheresis platelet concentrates.A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor.Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.The type 2B p.R1306W natural mutation of von Willebrand factor dramatically enhances the multimer sensitivity to shear stress.
P2860
Q24658043-97FA2890-FDF9-4F03-8E70-0608D9136755Q24670636-528CD201-AA15-4387-899E-79ECA33CF959Q26827966-EFDAAE3C-BA7B-48E8-9DCB-FC8A0754362AQ28248678-B9139374-2D23-44A8-A1A4-B27575279B65Q28584350-461D2AA9-1571-47B8-B89C-F12FB91FBBECQ30483148-87E132E6-587B-434F-8D68-0B0B8092AEBBQ30499388-4C6E1429-9926-4060-B0F7-A4BE0B6E981DQ31133820-4FDF660F-96BF-40AE-9980-39FD9C01FAC0Q33396071-59F4C140-2DB4-4E59-8489-50CA43D1668CQ33401086-FF6B1ECB-3755-4E82-A8AF-98CA66B174E6Q33402759-83C5E3DE-3934-4DB9-908F-7E810DA6CE74Q33426606-161B2C91-7696-4516-B0E4-B842707BFF45Q33442910-331C3524-7971-452F-A2A3-C10208DD469FQ34016608-8A4F46F6-6318-4A93-8C2E-645F1282110AQ34667787-400478D9-D96B-47F5-82E1-5FE1E21D024AQ34673739-AE242490-F297-4B02-8C37-C19895F508BAQ35553612-BF132C33-DAF1-4B86-A68A-9778FE94DBB0Q35836882-87BF3FD2-C277-46B6-9294-45B4C7719160Q36481209-FE8CDA2A-BA09-4486-9F7D-603D0B2313A3Q36528288-932DADB9-6EF0-4190-8BC4-3668CA7831F0Q36530522-9AAB943F-5D81-46BA-800C-AA3D4E4AA6B2Q36814657-176E6D66-3542-4D8B-9E97-6304769E3735Q37030936-CE6E8716-628F-49CC-98A0-E938F0FB9A7BQ37703427-D6286377-851F-472B-B2C7-6B244B944423Q37829737-AC7C3748-EA47-40CD-AF71-78ED5F0C8350Q38000162-477C9508-2D85-40F2-AC87-A8D36C0FD8E8Q38151739-3CA47563-5781-405C-89AF-46656AE3BD4DQ38160835-24A7D87D-F6C5-471A-A544-96C572808D90Q38303337-B97C2631-7234-45EE-85E8-F8FC9368EE47Q38413638-FD4B895B-A24C-4587-A85C-485474609221Q39410942-63BEE10D-BFAD-486C-A215-41236B23B97CQ41995651-6A95D767-B126-41A3-B01B-59DCBACE6C73Q42161898-D9B85458-71EE-4AE1-BD9E-F7DAFDD2FD8BQ45865145-C22EA478-C97D-4045-881A-FB2077CF2310Q45877995-82F7A4A0-BA9B-4FC5-9732-D4C12704C9B4Q46162832-92733D7B-B063-47DF-9585-C6680EF79F10Q48092153-53CBB212-2763-480A-805A-B593A1580BB1Q48152338-5A8C00F0-F7F8-4A11-9DC3-C273BF481347Q48214511-0F9E4072-3D59-4508-B460-169E39333142Q50863278-3EE248F9-C561-478B-BADA-E50C67F27750
P2860
A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
A novel nanobody that detects ...... on Willebrand disease type 2B.
@ast
A novel nanobody that detects ...... on Willebrand disease type 2B.
@en
type
label
A novel nanobody that detects ...... on Willebrand disease type 2B.
@ast
A novel nanobody that detects ...... on Willebrand disease type 2B.
@en
prefLabel
A novel nanobody that detects ...... on Willebrand disease type 2B.
@ast
A novel nanobody that detects ...... on Willebrand disease type 2B.
@en
P2093
P1433
P1476
A novel nanobody that detects ...... on Willebrand disease type 2B.
@en
P2093
Agnès Veyradier
Janine J J Hulstein
Karen Silence
Philip G de Groot
Rob Fijnheer
P304
P356
10.1182/BLOOD-2005-03-1153
P407
P577
2005-07-12T00:00:00Z